-
“One of the biggest innovations in hair loss we have seen in 25 years” – BosleyMD® partners with start-up Yuva Biosciences to launch groundbreaking technology nationwide1
-
Elevai Labs and Yuva Biosciences join forces for a breakthrough in hair and scalp care technology
NEWPORT BEACH, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) — Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneer in medical aesthetics, announces the filing of two innovative patents in collaboration with Yuva Biosciences. These patents support the development of Elevai’s innovative solutions for hair and scalp vitality. The first patent, “COMPOSITIONS AND METHODS FOR TREATING IMPROVEMENT OF SKIN, SCALP AND HAIR,” Patent Application No. 63/664,517, covers the unique and novel combination of Elevai exosomes and Y100, technologies that the inventors believe are synergistic and could produce significantly better results than either technology alone. The second patent, entitled “PREPARATIONS INCLUDING LIPID BILAYER NANOPARTICLES,” patent application number 63/664,526, addresses the use of exosomes (and similar lipid bilayer-based nanovesicles) as a unique delivery system while also serving to protect and preserve the delivered molecules.
Elevai Labs recently announced Elevai S-Series Root Renewal System™is an advanced three-part hair and scalp care system. This system includes Elevai’s proprietary PREx™ (“Precision Regenerative Exosome Technology”) and Yuva Biosciences’ Y100 mitochondrial technology. Already recognized and used by industry leader BosleyMD® in the national launch of Revive Plus Densifying Foam, Y100 technology plays an important role in treating common scalp and hair concerns such as thinning hair by promoting vitality and reversing signs of aging at the cellular level.
Yuva Biosciences has identified the Y100 mitochondrial technology that utilizes an advanced AI platform, “MitoGPT™, co-developed by their Chief Scientific Officer, Dr. Keshav K. Singh, and their leading AI team. This innovative technology, based on Dr. Singh’s groundbreaking research, has already been recognized as a valuable advancement in the fight against age-related hair and skin deterioration. Greg Schmergel, CEO of Yuva Biosciences, commented, “We are excited to partner with a scientific innovator like Elevai Labs to successfully combine our award-winning technologies and create revolutionary new products for the world of medical aesthetics. We look forward to helping people concerned about the signs of aging using the Elevai S-Series Root Renewal System.”
BosleyMD® has hailed Y100 technology as “one of the greatest innovations in hair loss in 25 years” and announced its first successful application in the company’s new product line. Elevai Labs’ integration of this technology into the Elevai S-Series Root Renewal System™ is expected to set a new standard in hair care, providing a scientifically validated, easy-to-use and cost-effective solution for men and women.
Elevai’s strategic vision for the future
Elevai Labs is poised to expand the application of its proprietary technologies beyond current applications. This upcoming product line was recently announced during a conference presentation for medical aesthetics professionals by Elevai Labs and Yuva Biosciences inventors and scientific co-founders Jordan R. Plews, PhD and Keshav K. Singh, PhD at the Aesthetic Show in Las Vegas, and the company plans to begin large-scale commercialization of the Elevai S-Series Root Renewal System™ in the near future. Given the proven efficacy of the underlying technologies, the S-Series is expected to generate significant interest among professional providers in the hair and scalp care market.
About Elevai Labs Inc.
Elevai Labs Inc. (NASDAQ: ELAB) is a medical aesthetics and biopharmaceutical drug development company focused on innovations for skin aesthetics and treatments related to obesity and metabolic health. The company operates a diverse portfolio of three wholly owned medical aesthetics and biopharmaceutical subsidiaries: Elevai Skincare Inc., Elevai Biosciences Inc. and Elevai Research Inc. For more information, visit www.elevailabs.com.
About Elevai Skincare Inc.
Elevai Skincare Inc., a subsidiary of Elevai Labs Inc., is a medical aesthetics company that develops and markets cutting-edge, physician-prescribed skin and hair care products. Elevai Skincare Inc. develops cosmetic products for the physician-prescribed market, focusing on the use of novel, proprietary, science-based technologies, including its stem cell exosome technology. For more information, visit www.elevaiskincare.com.
About Yuva Biosciences
Yuva Biosciences is an anti-aging company leveraging the latest in mitochondrial research to develop cosmeceuticals and drugs to treat age-related hair loss, wrinkled skin and a variety of other age-related conditions. The company’s scientific founder and chief scientific advisor, Keshav K. Singh, Ph.D., is a world-leading expert in mitochondrial biology and genetics and their role in health, disease and aging. Dr. Singh holds the Joy and Bill Harbert Endowed Chair and Professor of Genetics, Pathology and Dermatology at the University of Alabama at Birmingham and is the founding editor of the journal Mitochondrion, published by Elsevier. Yuva Biosciences is headquartered in Birmingham, Alabama. For more information, visit www.yuvabio.com.
Forward-looking statements
Statements in this press release that address matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward to” are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it cannot assure you that these expectations will prove to be correct and the Company cautions investors that actual results may differ materially from those anticipated. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, regulatory activities and future regulations, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are beyond our control. Therefore, you should not rely on these forward-looking statements. These risks and uncertainties include, among others: Elevai’s limited operating history and historical losses; Elevai’s ability to raise additional funding to complete the development and eventual commercialization of its product candidates; Elevai’s dependence on the success of its EL-22 and EL-32 product candidates; that Elevai may experience delays in initiating, enrolling or completing clinical trials; competition from third parties developing products for similar uses; Elevai’s ability to obtain, maintain and protect its intellectual property; Elevai’s dependence on third parties for manufacturing, clinical testing and preclinical studies; and Elevai’s expectations regarding its growth, strategy, progress and the design, objectives and timing of its trials.
These and other risks are described more fully in Elevai Labs’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 29, 2024, and other documents subsequently filed with or furnished to the SEC. Any forward-looking statements included in this press release speak only as of the date they are made. Except as required by law, the Company undertakes no obligation to update such statements to reflect events or circumstances that occur after the date they are made.
Media contact: Makenzie Mann
Email: [email protected]
1 “One of the biggest innovations in hair loss we have seen in 25 years” – BosleyMD® partners with startup Yuva Biosciences to roll out breakthrough technology nationwide | Business Wire
